Featured Attorney

Adam D. Michel

Associate

Adam D. Michel practices in the Firm’s Complex Litigation, Pharmaceutical Products, and Toxic Torts & Products Liability groups.  His experience spans virtually the entire litigation process, and he has substantial first-chair experience representing clients at hearings, pretrial conferences, and mediation. Read More >

Search Hollingsworth LLP's opinions from across the country. >

Precedents

• The Zometa® Cases

  Hollingsworth LLP outwits well-funded plaintiffs' attorney group by prevailing in early trials (including plaintiffs' trial picks) in consolidated litigation for client Novartis Pharmaceuticals Corporation.

• The Parlodel® Trilogy

  11th Circuit affirmance in Rider v. Sandoz Pharmaceuticals completes circuit court Daubert sweep in Parlodel® litigation.

• Favorable settlement reached for Norfolk Southern in largest single tort case in South Carolina history

  Avondale Mills, Inc. v. Norfolk Southern Corp., Civ. No. 1:05-2817-MBS (D.S.C. 2008)

• Court dismissed $4B claim brought by the State of New Mexico against Firm client General Electric.

  New Mexico v. Gen. Electric Co., 467 F.3d 1223 (10th Cir. 2006)

• Federal court grants Daubert and summary judgment motions filed by Firm client General Motors in PCB lawsuit.

  Allgood v. General Motors Corp., No. 1:02-cv-1077-DFH-TAB (S.D. Ind. Sept. 18, 2006)

Verdicts & Opinions

• Idaho court dismisses innovator liability claims against Novartis for lack of specific personal jurisdiction.

  Stirling v. Novartis Pharm. Corp., No. CV01-18-4880 (Idaho 4th Jud. Dist., Ada Cty. July 13, 2020)

• Firm secures voluntary dismissal with prejudice for Novartis.

  Coleson v. Novartis Pharm. Corp., No. 3:18-cv-00359, (S.D. Miss. June 29, 2020)

• Texas district court judge rejects innovator claims against Firm client Novartis Pharmaceuticals Corporation.

  Johnson v. Novartis Pharm. Corp., et al., No. 5:19-cv-01087-OLG (May 7, 2020). 

• Idaho state court rejects innovator liability claims against Firm client Novartis Pharmaceuticals Corporation.

  Stirling v. Novartis Pharm. Corp., et al., No. CV01-18-4880 (Sept. 25, 2019)

• Federal district court dismisses putative class action against Sherwin-Williams.

  Brad Lafferty, et al. v. The Sherwin-Williams Company, et al., Case No. 1:17-cv-06321, at *8 (D.N.J. Aug. 21, 2018)